Pharmacokinetic interaction involving Sorafenib and the calcium-channel blocker felodipine in a patient with hepatocellular carcinoma

Investigational New Drugs

Volumn 29, Issue 6, 2011, Pages 1511-1514

  Gomo, Charline ^a   Coriat, Romain ^a,b   Faivre, Lionel ^a   Mir, Olivier ^a,b   Ropert, Stanislas ^a,b   Billemont, Bertrand ^a   Dauphin, Alain ^a   Tod, Michel ^c,d   Goldwasser, Francois ^a,b   Blanchet, Benoit ^a  

^a HÔTEL DIEU   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c CROIX ROUSSE HOSPITAL   (France)

^d UNIVERSITÉ DE LYON   (France)

Author keywords

CYP3A4 drug drug interaction; Felodipine; Hypertension; Sorafenib

Indexed keywords

ADEFOVIR DIPIVOXIL; ALBUMIN; BILIRUBIN; FELODIPINE; FUROSEMIDE; LAMIVUDINE; PROPRANOLOL; SORAFENIB; ANTINEOPLASTIC AGENT; BENZENESULFONIC ACID DERIVATIVE; CALCIUM CHANNEL BLOCKING AGENT; CYP3A4 PROTEIN, HUMAN; CYTOCHROME P450 3A; PYRIDINE DERIVATIVE;

AGED; ALBUMIN BLOOD LEVEL; ANOREXIA; ARTICLE; ASTHENIA; BILIRUBIN BLOOD LEVEL; CANCER CHEMOTHERAPY; CANCER GROWTH; CASE REPORT; DIARRHEA; DISEASE SEVERITY; DOSE RESPONSE; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG SAFETY; DRUG WITHDRAWAL; HOARSENESS; HUMAN; HYPERTENSION; LIVER CELL CARCINOMA; LIVER EXAMINATION; MALE; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; SKIN DISEASE; CHEMICALLY INDUCED DISORDER; DRUG INTERACTION; LIVER TUMOR; METABOLISM; PATHOLOGY;

AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CALCIUM CHANNEL BLOCKERS; CARCINOMA, HEPATOCELLULAR; CYTOCHROME P-450 CYP3A; DRUG INTERACTIONS; FELODIPINE; HUMANS; HYPERTENSION; LIVER NEOPLASMS; MALE; PYRIDINES;

EID: 84856025247     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-010-9514-3     Document Type: Article

References (16)

1. Kolch W, Kotwaliwale A, Vass K, Janosch P (2002) The role of raf kinases in malignant transformation. Expert Rev MolMed 4(8):1-18
2. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, Cao Y, Shujath J, Gawlak S, Eveleigh D, Rowley B, Liu L, Adnane L, Lynch M, Auclair D, Taylor I, Gedrich R, Voznesensky A, Riedl B, Post LE, Bollag G, Trail PA (2004) Bay 43-9006 exhibits broad spectrum oral antitumor activity and targets the raf/mek/erk pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64(19):7099-7109 (Pubitemid 39331023)
3. Carlomagno F, Anaganti S, Guida T, Salvatore G, Troncone G, Wilhelm SM, Santoro M (2006) Bay 43-9006 inhibition of oncogenic ret mutants. J Natl Cancer Inst 98(5):326-334 (Pubitemid 43338212)
4. Wilhelm SM, Adnane L, Newell P, Villanueva A, Llovet JM, Lynch M (2008) Preclinical overview of sorafenib, a multikinase inhibitor that targets both raf and vegf and pdgf receptor tyrosine kinase signaling. Mol Cancer Ther 7(10):3129-3140
5. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Haussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359(4):378-390
6. Blanchet B, Billemont B, Barete S, Garrigue H, Cabanes L, Coriat R, Frances C, Knebelmann B, Goldwasser F (2010) Toxicity of sorafenib: clinical and molecular aspects. Expert Opin Drug Saf 9(2):275-287
7. van Erp NP, Gelderblom H, Guchelaar HJ (2009) Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat Rev 35(8):692-706
8. Blanchet B, Billemont B, Cramard J, Benichou AS, Chhun S, Harcouet L, Ropert S, Dauphin A, Goldwasser F, Tod M (2009) Validation of an hplc-uv method for sorafenib determination in human plasma and application to cancer patients in routine clinical practice. J Pharm Biomed Anal 49(4):1109-1114
9. Lathia C, Lettieri J, Cihon F, Gallentine M, Radtke M, Sundaresan P (2006) Lack of effect of ketoconazole-mediated cyp3a inhibition on sorafenib clinical pharmacokinetics. Cancer Chemother Pharmacol 57(5):685-692
10. Horn J, Hansten P, Chan L (2007) Proposal for a new tool to evaluate drug interaction cases. Ann Pharmacother 41:674-680 (Pubitemid 46625492)
11. Abou-Alfa GK, Schwartz L, Ricci S, Amadori D, Santoro A, Figer A, De Greve J, Douillard JY, Lathia C, Schwartz B, Taylor I, Moscovici M, Saltz LB (2006) Phase ii study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 24(26):4293-4300 (Pubitemid 46630787)
12. Furuse J, Ishii H, Nakachi K, Suzuki E, Shimizu S, Nakajima K (2008) Phase i study of sorafenib in japanese patients with hepatocellular carcinoma. Cancer Sci 99(1):159-165 (Pubitemid 350239045)
13. European Medicines Agency Sorafenib (nexavar): Summary of product characteristics [online]. Available from url: http://www.Emea.Europa.Eu/ humandocs/pdfs/epar/nexavar/h-690-pi-en.Pdf.
14. Barbier O, Girard H, Inoue Y, Duez H, Villeneuve L, Kamiya A, Fruchart JC, Guillemette C, Gonzalez FJ, Staels B (2005) Hepatic expression of the ugt1a9 gene is governed by hepatocyte nuclear factor 4alpha. Mol Pharmacol 67(1):241-249 (Pubitemid 40069984)
15. Tanaka T, Jiang S, Hotta H, Takano K, Iwanari H, Sumi K, Daigo K, Ohashi R, Sugai M, Ikegame C, Umezu H, Hirayama Y, Midorikawa Y, Hippo Y, Watanabe A, Uchiyama Y, Hasegawa G, Reid P, Aburatani H, Hamakubo T, Sakai J, Naito M, Kodama T (2006) Dysregulated expression of p1 and p2 promoter-driven hepatocyte nuclear factor-4alpha in the pathogenesis of human cancer. J Pathol 208(5):662-672
16. Lazarevich NL, Cheremnova OA, Varga EV, Ovchinnikov DA, Kudrjavtseva EI, Morozova OV, Fleishman DI, Engelhardt NV, Duncan SA (2004) Progression of hcc in mice is associated with a downregulation in the expression of hepatocyte nuclear factors. Hepatology 39(4):1038-1047 (Pubitemid 38428943)